View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Uncategorised
May 18, 2021

Coronavirus company news summary – Eurofins develops new tests to detect emerging Covid-19 variants of concern – MyHealthChecked and Boots sign Covid-19 test contract

By Chloe Kent

Eurofins Technologies has launched two new tests: the GSD NovaPrime Plus SARS-CoV-2, a PCR test to detect key mutations of variants of concern in one reaction, and the GSD NovaType Select L452R SARS-CoV-2 (RUO), to detect critical variants such as the ones found in California, India and the US. Eurofins is expected to invest further in the development of reliable and high-quality Covid-19 and variant testing solutions.

ZEUS Scientific, a medical equipment manufacturer, announced that the US Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) to its in vitro ELISA diagnostic test to detect total (IgG/IgM/IgA) antibodies against the SARS-CoV-2 virus in human serum and plasma. This test is expected to be readily available to all clinical laboratories in the country.

MyHealthChecked announced that it has signed a second contract with UK pharmaceutical retailer Boots for its at-home Covid-19 nasal swab test kit. The agreement extends its offering to include tests for international arrivals to the UK, on the second and eighth day of their arrival. The test is expected to be available on the Boots website.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Medical Device Network